Four multinational pharmaceutical companies are among 10 new members of a consortium that has been formed to reach consensus on standards and tools for developing new drugs to treat tuberculosis that might then be adopted by drug regulators. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
